HP

Hanmi Pharmaceutical at ObesityWeek 2026

Nov 14–17, 2026 National Harbor, MD ~4.4k attendees Website

Hanmi Pharmaceutical brings 5 presentations to ObesityWeek 2026 in National Harbor. Its posters center on long-acting peptide drugs, including the myostatin inhibitor HM500197, which preserves muscle mass during weight loss alongside incretin therapy. Others test the GLP-1/GIP/glucagon triple agonist HM15275 against dyslipidemia and obesity-associated colorectal cancer.

OrganizationObesityWeek 2026 Attendance
HP
Hanmi Pharmaceutical
Seoul, South Korea
Large pharma
Pharmaceutical company developing long-acting incretin drugs, including efpeglenatide and the triple agonist HM15275, plus muscle-preserving candidates.
Poster
Mon Nov 16
2:30pm–3:30pm

Explore the full ObesityWeek 2026 dataset

Get in-depth attendee and institution profiles and research, to plan your meetings in National Harbor. Leave your work email and we’ll be in touch.

Privacy

Download the full ObesityWeek 2026 CSV

Leave your work email and we’ll be in touch. The CSV adds attendee names, roles and contact details to the company and session data shown here.

Privacy

Find decision makers at Hanmi Pharmaceutical

Tell us what you sell and we’ll find the people at Hanmi Pharmaceutical most likely to buy it.

  • Who to contact
  • Their contact info
  • What to say
  • Free, no sign-up

Not affiliated with or endorsed by The Obesity Society (TOS), ObesityWeek® or the American Society for Metabolic and Bariatric Surgery (ASMBS). Submit a correction